FREE COMMUNICATION 18

17.00-18.30   FORUM

 

New dialysis techniques
 

Chairs: Peter Barany, Stockholm, Sweden
             Francisco Maduell, Barcelona, Spain
 
Mini lecture
High-flux hemodialysis - Time to rethinking
Andreas Schneider, Würzburg, Germany
 
FREE COMMUNICATIONS
 
MO035
MORTALITY DURING EXTENDED FOLLOW-UP IN THE FREQUENT HEMODIALYSIS NETWORK
NOCTURNAL TRIAL
Michael Rocco1, John Daugirdas2, Tom Greene3, Robert Lockridge4, Christopher Chan5, Andreas Pierratos5, Robert Lindsay6, Brett Larive7, Glenn Chertow8, Gerald Beck7, Paul Eggers9, Alan Kliger10, for the FHN Trial Group 1Wake Forest Univ, Winston-Salem, NC; 2Univ Illinois, Chicago, IL; 3Univ Utah, Salt Lake City, UT; 4Univ Virginia, Lynchburg, VA; 5Univ Toronto, Toronto, ON, Canada, 6London Health Sciences, London, ON, Canada, 7Cleveland Clinic, Cleveland, OH; 8Stanford Univ, Stanford, CA; 9NIH/NIDDK, Bethesda, MD; 10Yale New Haven Hosp, New Haven, CT
 
MO036
A RANDOMIZED CONTROLLED MULTICENTER TRIAL OF A HEPARIN-GRAFTED POLYACRYLONITRILE
MEMBRANE FOR NO-HEPARIN HEMODIALYSIS VERSUS STANDARD-OF-CARE: RESULTS
OF THE HEPZERO STUDY
Maurice Laville1, Marc Dorval2, Joan Fort Ros3, Renaud Fay4, Joelle Cridlig5, Joelle L Nortier6, Laurent Juillard7, Alicja Dębska-Ślizień8, Loreto Fernandez Lorente9, Damien Thibaudin10, Casper FM Franssen11, Michael Schulz12, Frederique Moureau13, Nathalie Loughraieb13, Patrick Rossignol4
1Lyon-Sud Hosp; Lyon Univ; Aural, Lyon, France, 2Dr Georges-L-Dumont Univ Hosp, Moncton, NB,
Canada, 3Univ Hosp Vall d’Hebron, Autonomous Univ, Barcelona, Spain, 4INSERM CIC, Nancy Univ
Hosp; Lorraine Univ; ALTIR, Nancy, France, 5Nancy Univ Hosp; Lorraine Univ, Nancy, France, 6Erasme Univ Hosp, Brussels, Belgium, 7Edouard Herriot Univ Hosp, Lyon, France, 8Medical Univ GdańSk, Gdańsk, Poland, 9Germans Trias i Pujol Hosp, Badalona, Spain, 10Saint-Etienne Univ Hosp, Saint-Etienne, France, 11Univ Medical Center Groningen, Groningen, Netherlands, 12Royal Liverpool Broadgreen Univ Hosp, Liverpool, UK, 13Gambro Hospal, Meyzieu, France
 
MO037
LONG-TERM EFFECTS OF FREQUENT IN-CENTER HEMODIALYSIS: FHN DAILY TRIAL
Alan S Kliger1, Glenn M Chertow2, Nathan W Levin3, Gerald J Beck4, John T Daugirdas5, Paul W Eggers6, Brett Larive4, Michael V Rocco7, Tom Greene8 1Yale Univ School of Medicine, New Haven, CT; 2Stanford Univ, Stanford, CA; 3Renal Research Inst, New York, NY; 4Cleveland Clinic Foundation, Cleveland, OH; 5Univ Illinois, Chicago, IL; 6National Inst Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 7Wake Forest Univ School of Medicine, Winston-Salem, NC; 8Univ Utah, Salt Lake City, UT

 

MO038
MODIFIABLE FACTORS ASSOCIATED WITH THE ACHIEVEMENT OF HIGH-VOLUME POST-DILUTION
HEMODIAFILTRATION
Daniele Marcelli1, Tomas Jirka2, José I Merello3, Pedro Ponce4, Erzsebet Ladanyi5, Attilio Di Benedetto6, Jaroslav Rosenberger7, Stefano Stuard1, Caecilia Scholz1, Bernard Canaud8 1Fresenius Medical Care, Bad Homburg, Germany, 2Fresenius Medical Care, Prague, Czech Republic, 3Nephrocare Spain, Madrid, Spain, 4Nephrocare Portugal, Lisbon, Portugal, 5FMC Miskolci Nefrológiai Központ, Miskolc, Hungary, 6Nephrocare Italy, Naples, Italy, 7Nephrocare Slovakia, Kosice, Slovakia,
8Montpellier Univ I, Montpellier, France
 
MO039
NEPHRON+ WEARABLE ARTIFICIAL KIDNEY DEVICE
Frank Simonis1, Leonidas Lymberopoulos2, Marc Correvon3, Sjoukje Wiegersma4, Jasper Boomker5,
Hassan Anis6, Julien Fils7, Jens Hartmann8, Maarten Wester9, Frank Poppen10
1Nanodialysis, Oirschot, Netherlands, 2EXUS SA, Athens, Greece, 3CSEM, Neuchâtel, Switzerland,
4TNO, Eindhoven, Netherlands, 5Nierstichting, Bussum, Netherlands, 6IMST, Kamp Lintfort, Germany,
7CEA-LETI, Grenoble, France, 8Donau Univ, Krems, Austria, 9UMCU, Utrecht, Netherlands, 10Offis,
Oldenburg, Germany
    

back to the timetable